Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) COGS-to-Revenue

: 0.34 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Takeda Pharmaceutical Co's Cost of Goods Sold for the three months ended in Dec. 2023 was $2,636 Mil. Its Revenue for the three months ended in Dec. 2023 was $7,718 Mil.

Takeda Pharmaceutical Co's COGS to Revenue for the three months ended in Dec. 2023 was 0.34.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Takeda Pharmaceutical Co's Gross Margin % for the three months ended in Dec. 2023 was 65.85%.

Takeda Pharmaceutical Co COGS-to-Revenue Historical Data

The historical data trend for Takeda Pharmaceutical Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

0.31

0.33

0.31

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue																0.31	0.32	0.30	0.33	0.34

Takeda Pharmaceutical Co COGS-to-Revenue Calculation

Takeda Pharmaceutical Co's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	9307.437	/	30131.292
	=	0.31

Takeda Pharmaceutical Co's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2635.623	/	7717.561
	=	0.34

Takeda Pharmaceutical Co (NYSE:TAK) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Takeda Pharmaceutical Co's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2635.623 / 7717.561
	=	65.85 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Takeda Pharmaceutical Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.